GOV Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Revenue Scale & MarginsInsulet’s durable revenue scale and consistently high gross margins reflect a repeat-consumables business (pods) with strong unit economics. Large recurring demand and >60% gross margins create steady cash conversion potential, support R&D and manufacturing investment, and protect long-term profitability versus peers.
Improved Cash Generation & Balance SheetSustained positive operating cash flows and meaningful free cash flow provide durable financial flexibility to fund capex, R&D and buybacks while reducing refinance risk. A stronger equity base and lower leverage broaden the company’s margin for error during product transitions or cyclical stress.
Product Pipeline & International MomentumRobust international expansion and a multi‑year product roadmap (sensor integration, algorithm upgrades, Omnipod 6, closed‑loop type 2) strengthen market position. These structural innovations deepen clinical value, broaden addressable markets, raise switching costs, and underpin sustained revenue growth across geographies.
Bears Say
Medical Device Corrections & Regulatory ScrutinyLarge-scale product corrections create persistent reputational and regulatory risk; replacements and remediation raise costs and invite closer scrutiny from regulators and payers. Even with provisioned costs, such events can slow adoption, complicate reimbursement and increase compliance/headcount needs over multiple quarters.
Retention Risk And Channel CompetitionA shift toward more type 2 patients (higher early attrition) and intensifying pharmacy‑channel competition can structurally lower lifetime value and raise rebate/marketing spend. Over time, this dynamic can compress margins, increase customer acquisition costs, and require sustained commercial investment to preserve unit economics.
Transition Costs, CapEx Ramp & Cash ConversionOngoing product transitions and a stepped-up manufacturing capex program pressure near-term margins and free cash flow. Historical FCF is only ~66–71% of net income, indicating material reinvestment needs; prolonged transitions or higher-than-expected capex could restrain cash returns and margin sustainability.
Insulet News
GOV FAQ
What was Insulet’s price range in the past 12 months?
Currently, no data Available
What is Insulet’s market cap?
Insulet’s market cap is CHF9.15B.
When is Insulet’s upcoming earnings report date?
Insulet’s upcoming earnings report date is Aug 05, 2026 which is in 31 days.
How were Insulet’s earnings last quarter?
Insulet released its earnings results on May 06, 2026. The company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.963 by $0.177.
Is Insulet overvalued?
According to Wall Street analysts Insulet’s price is currently Undervalued.
Does Insulet pay dividends?
Insulet does not currently pay dividends.
What is Insulet’s EPS estimate?
Insulet’s EPS estimate is 1.16.
How many shares outstanding does Insulet have?
Currently, no data Available
What happened to Insulet’s price movement after its last earnings report?
Insulet reported an EPS of $1.14 in its last earnings report, beating expectations of $0.963. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Insulet?
Currently, no hedge funds are holding shares in CH:GOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insulet Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF185.67 (― Downside)
CHF185.67 (― Downside)
Insider Transactions
Bought Shares
Worth CHF677.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 60%
Bearish news 40%
Bearish news 40%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.46%
12-Months-Change
Fundamentals
Return on Equity
21.38%
Trailing 12-Months
Asset Growth
-15.07%
Trailing 12-Months
Company Description
Insulet
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
GOV Company Deck
GOV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: robust revenue growth (30% constant-currency company; 45% international), margin expansion, ~40% EPS growth, raised full-year guidance, product R&D progress (Libre 3 Plus integration, Omnipod 6, fully closed-loop type 2) and healthy cash generation and buybacks. Offsetting items were largely identifiable, management-described headwinds and investments — including a voluntary medical device correction with related costs (~$12M), excess & obsolescence charges during a product transition (impacting gross margin >150 bps), short-term seasonality affecting Q1 U.S. new customer starts, modest retention pressure as type 2 mix grows, and elevated interest/cost pressures. Overall, positives (strong growth, margin expansion, product pipeline, guidance raise and cash actions) materially outweigh the disclosed challenges, which management framed as manageable, partly one-time, or investments to support durable growth.View all CH:GOV earnings summariesGOV Revenue Breakdown
70.89% U.S. Omnipod
27.85% International Omnipod
1.26% Drug Delivery
GOV Stock 12 Month Forecast
Average Price Target
$185.67
Dexcom
―
Koninklijke Philips
―
Steris
―
Zimmer Biomet Holdings
―
Tandem Diabetes Care
―
Options Prices
Currently, No data available
---